A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients.

CONCLUSIONS: These results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted. PMID: 30786922 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/30786922?dopt=Abstract

Source: Clinical Breast Cancer - February 20, 2019 Category: Cancer & Oncology Authors: Pineda B, Diaz-Lagares A, Pérez-Fidalgo JA, Burgués O, González-Barrallo I, Crujeiras AB, Sandoval J, Esteller M, Lluch A, Eroles P Tags: Clin Epigenetics Source Type: research